StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a research note issued to investors on Monday morning. The firm issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
Shares of Brooklyn ImmunoTherapeutics stock opened at $1.89 on Monday. The business’s 50 day moving average price is $1.98 and its 200 day moving average price is $1.98. The company has a market cap of $110.89 million, a price-to-earnings ratio of -0.83 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10.
About Brooklyn ImmunoTherapeutics
Featured Articles
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- How to Invest in Small Cap StocksĀ
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- 3 Tickers Leading a Meme Stock Revival
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.